Abstract:
A review of preclinical and clinical data of a new migraine management was made, which still remains a problem. Migraine treatment has evaluated in the last decade, several new approaches to the treatment of migraine have been substantially advanced, including selective 5-hydroxytryptamine (or serotonin) 1B/1D (5-HT1B/1D) receptor agonists such as sumatriptan, developments of second generation triptans (zolmitriptan, rizatriptan, naratriptan) and a new class of drugs 5-HT(1F) receptor agonists such as LY344864.
A fost efectuată o revizuire a datelor preclinice şi clinice în managementul migrenei, care rămâne o problemă în continuare. Tratamentul migrenei a evoluat în ultimul deceniu, au fost avansate substanţial multe abordări noi antimigrenoase, inclusiv agoniştii selectivi ai receptorilor 5-hidroxitriptamina (serotonina) 1B/1D (5-HT1B/1D), cum ar fi sumatriptan, apariţia triptanilor de generaţia doua (zolmitriptan, rizatriptan, naratriptan) şi o nouă clasă de medicamente, agoniştii receptorilor 5-HT (1F), cum ar fi LY344864.
